17-HETE is an arachidonic acid metabolite produced through the cytochrome P-450 pathway and consists of 17R-HETE and 17S-HETE enantiomers. 17-HETE can act as an allosteric activator and ATPase inhibitor of cytochrome P450 1B1 and can induce cardiac hypertrophy.

Physicochemical Properties

Molecular Formula	C20H32O3
Molecular Weight	320.47
Exact Mass	320.235
CAS #	128914-47-6
PubChem CID	6442740
Appearance	Typically exists as solid at room temperature
Density	0.984g/cm3
Boiling Point	477.3ºC at 760 mmHg
Flash Point	256.6ºC
Vapour Pressure	4.1E-11mmHg at 25°C
Index of Refraction	1.513
LogP	5.187
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	14
Heavy Atom Count	23
Complexity	392
Defined Atom Stereocenter Count	0
SMILES	CCCC(C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O)O
InChi Key	OPPIPPRXLIDJKN-JPURVOHMSA-N
InChi Code	InChI=1S/C20H32O3/c1-2-16-19(21)17-14-12-10-8-6-4-3-5-7-9-11-13-15-18-20(22)23/h3,5-6,8-9,11-12,14,19,21H,2,4,7,10,13,15-18H2,1H3,(H,22,23)/b5-3-,8-6-,11-9-,14-12-
Chemical Name	(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoic acid
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	CYP1B1
ln Vitro	17-HETE (5-20 μM) promotes the development of human cardiac hypertrophy by increasing the activity and protein levels of CY1B1[1]. Real Time qPCR[1] Cell Line: AC16 Concentration: 5-20 µM Incubation Time: 24 h Result: Increased mRNA levels of β-MHC and ANP, increased cell surface area.
ln Vivo	17-HETE (1-20 μg, intra-arterial injection) stereospecifically (S-enantiomer) inhibits proximal tubule ATPase activity in New Zealand white rabbits [2].
Cell Assay	Western Blot Analysis[1] Cell Types: AC16 Concentration: 20 µM Incubation Duration: 24 h Experimental Results: Increased expression of CYP 1B1.
Animal Protocol	Animal/Disease Models:New Zealand White rabbit[2] Doses: 1-20 μg Route of Administration: injection into artery Experimental Results: 17S inhibited more than 70% ATPase activity at the concentration of 2 μM, while 17R enantiomer remained inactive.
ADME/Pharmacokinetics	Metabolism / Metabolites 17-HETE is a known human metabolite of arachidonic acid.
References	[1]. 17-(R/S)-hydroxyeicosatetraenoic acid (HETE) induces cardiac hypertrophy through the CYP1B1 in enantioselective manners. Prostaglandins Other Lipid Mediat. 2023 Oct;168:106749. [2]. Cytochrome P-450-dependent HETEs: profile of biological activity and stimulation by vasoactive peptides. Am J Physiol. 1996 Oct;271(4 Pt 2):R863-9.
Additional Infomation	17-HETE is a HETE that consists of arachidonic acid bearing an additional hydroxy substituent at position 17. It is functionally related to an icosa-5,8,11,14-tetraenoic acid. It is a conjugate acid of a 17-HETE(1-).

Solubility Data

Solubility (In Vitro)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Solubility (In Vivo)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.1204 mL	15.6021 mL	31.2042 mL
	5 mM	0.6241 mL	3.1204 mL	6.2408 mL
	10 mM	0.3120 mL	1.5602 mL	3.1204 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.